AMOMED Pharma develops medicinal products for patients suffering from septic shock at the intensive care units. Septic shock is a life-threatening complication in COVID-19 patients.
Most COVID-19 admissions to the intensive care unit are due to severe lung disorders requiring invasive mechanical ventilation; many with acute respiratory distress syndrome. Acute respiratory distress syndrome (ARDS) is associated with a higher incidence of pulmonary arterial hypertension.
Experimental studies showed that pulmonary arteries were not constricted with arginine-vasopressin in contrast to conventional vasopressors.
Vasopressin is a natural hormone produced in the pituitary gland that controls the narrowing (constriction) and widening (dilation) of blood vessels. The body has a severe deficit of this substance in septic shock. Vasopressin, together with norepinephrine, can help to stabilize critically low blood pressure in septic shock.
AMOMED Pharma is the only pharmaceutical company in the European Union with an approval for the use of arginine-vasopressin for catecholamine refractory hypotension in septic shock to raise mean arterial blood pressure. The use of arginine vasopressin in the treatment of COVID-19 in septic shock has now been included in national and international guidelines1.
Clinicians and other healthcare professionals can register at https://www.amomed.com/register/?lang=en to learn more about the applicable patient profile for arginine-vasopressin. If you have any questions about the effects of vasopressin, please contact us at [email protected].
The current COVID-19 outbreak has become an enormous challenge for hospitals and medical staff. The AMOMED team would like to thank everyone in the healthcare sector for this enormous effort.